Plain-English translation of NCT07389616 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether two medications — Cidabenamine combined with Azacitidine — can help keep peripheral T-cell lymphoma from progressing after you have had an allogeneic stem cell transplant. These medications are given as a maintenance therapy, meaning they continue your treatment after the transplant itself is complete. The study involves about 40 patients and will carefully monitor how well this combination works and how safe it is.
Peripheral T-cell lymphoma is an aggressive blood cancer, and even after a successful stem cell transplant, there is a risk it could come back. This trial aims to find out whether this medication combination can reduce that risk and help keep the cancer from progressing in patients who had high-risk disease before their transplant.
You likely qualify if…
You likely don't qualify if…
You will attend a screening visit where doctors will review your medical history, check your vital signs, and run tests including imaging scans, bone marrow samples, and blood work to make sure you qualify. Once enrolled, you will receive the two-medication combination as maintenance therapy following your stem cell transplant. You will have regular follow-up visits to monitor how well the treatment is working and check for any side effects, with assessments similar to those done at baseline.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China